The short version of research chemical fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-02 and is reviewed periodically as new material appears.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
a primary alcohol + halide Thus, the two substrates of this enzyme are 1-haloalkane and H2O, whereas its two products are primary alcohol and halide. This enzyme belongs to the family of hydrolases, specifically those acting on halide bonds in carbon-halide compounds. The systematic name of this enzyme class is 1-haloalkane halidohydrolase. Other names in common use include 1-chlorohexane halidohydrolase, and 1-haloalkane dehalogenase. Haloalkane dehalogenases are found in certain bacteria and belong the alpha-beta hydrolase fold superfamily of enzymes. They participate in several metabolic pathways: 1,2-dichloroethane degradation, 1-chloro-n-butane degradation, hexachlorocyclohexane degradation, 1,2-dibromoethane degradation, 2-chloroethyl-vinylether degradation, and 1,3-dichloropropene degradation.
a chiral stationary phase or a chiral additive in the mobile phase. The chiral stationary phase can be prepared by mixing chirally pure reagents such as L-amino acid, or brucine, or a chiral ligand exchange reagent with silica gel slurry, or by impregnation of the TLC plate in the solution of a chiral reagent. The principle can also be applied to chemically modify the stationary phase before making the plate via bonding of the chiral moieties of interest to the reactive groups of the layer material.
The governor of Minas Gerais, Romeu Zema, said he hoped that Maduro's downfall would allow Venezuela to "rediscover peace, stability and the path to development". The governor of Goiás, Ronaldo Caiado, said that "this 3 January goes down in history as the day of the liberation of the Venezuelan people, who have lived for more than 20 years under a"Chavista narco-dictatorship". Senator Flávio Bolsonaro (PL-RJ) publicly celebrated the capture of Maduro by the United States, describing the event as a historic milestone for freedom and democracy. He said that Venezuela had become one of the most extreme examples of "how an authoritarian regime can destroy a nation". Michelle Bolsonaro, former First Lady of Brazil and the president of the women's movement under the Liberal Party, PL Mulher, stated that the U.S. action represents the "beginning of the end of the authoritarian and criminal regime" of Venezuela and a message for "dictators disguised as democrats and defenders of drug traffickers".
Sources: en.wikipedia.org
Mutant+Chimeric+Proteins at the U.S. National Library of Medicine Medical Subject Headings (MeSH) ChiPPI Archived 2021-11-10 at the Wayback Machine: The Server Protein–Protein Interaction of Chimeric Proteins.
In this process, an electron from the analyte molecule (M) is expelled during the collision process to convert the molecule to a positive ion with an odd number of electrons. The following gas phase reaction describes the electron ionization process
== Evolution == Serpins are the most widely distributed and largest superfamily of protease inhibitors. They were initially believed to be restricted to eukaryote organisms, but have since been found in bacteria, archaea and some viruses. It remains unclear whether prokaryote genes are the descendants of an ancestral prokaryotic serpin or the product of horizontal gene transfer from eukaryotes. Most intracellular serpins belong to a single phylogenetic clade, whether they come from plants or animals, indicating that the intracellular and extracellular serpins may have diverged before the plants and animals. Exceptions include the intracellular heat shock serpin HSP47, which is a chaperone essential for proper folding of collagen, and cycles between the cis-Golgi and the endoplasmic reticulum. Protease-inhibition is thought to be the ancestral function, with non-inhibitory members the results of evolutionary neofunctionalisation of the structure. The S to R conformational change has also been adapted by some binding serpins to regulate affinity for their targets.
Sources: en.wikipedia.org
Polyendocrine metabolic ovarian syndrome (PMOS), previously called polycystic ovary syndrome (PCOS), is the most common hormonal disorder in women of reproductive age. PMOS is diagnosed when a woman has at least two of the following three features: irregular menstrual periods, high testosterone or related symptoms (like excess facial hair), or an excess of antral ovarian follicles on ultrasound. Persons with PMOS are not more likely than those without to have true ovarian cysts. A blood test for high levels of anti-Müllerian hormone can replace the ultrasound in the diagnosis. Other symptoms associated with PMOS are heavy periods, acne, difficulty getting pregnant, and patches of darker skin. The exact cause of PMOS remains uncertain. There is a clear genetic component, but environmental factors are also thought to contribute. PMOS occurs in between 5% and 18% of women. The disorder is linked to insulin resistance, which is made worse by obesity. Insulin resistance and related excess insulin levels increase the risk of complications such as type 2 diabetes and liver disease. Those living with PMOS also have higher risk of endometrial cancer.
Thomas Sullivan is credited with inventing tea bags in 1908. Sullivan, a New York tea importer, inadvertently invented tea bags when he sent tea samples to clients in small silk bags to cut costs, and they mistakenly steeped the bags whole. The customers were more interested in the brewing convenience of the novel silk bags than his bulk teas. Sullivan did not realize this until they all started to complain that the orders they received were not in the same small bags the samples had been in. Silk was too expensive for everyday disposal; therefore, he invented tea bags made of gauze. The tea bag made of paper fiber was a later American invention. The nylon pyramidal tea bag containing broken teas and semi-leaf teas made an appearance in the marketplace for aficionados. The pyramidal shape - it is said - allows more room for the leaf to steep. Environmentalists prefer silk to nylon because of the health and biodegradability issues. Most tea sold in the United States is sold in bags, although loose leaf teas and iced are also available.
=== Neurotoxic reactions === Headache, mild depression, mental confusion, and delirium have been described in patients receiving chloramphenicol. Optic and peripheral neuritis have been reported, usually following long-term therapy. If this occurs, the drug should be promptly withdrawn. It is theorized that this is caused by chloramphenicol's effects on the metabolism of B-Vitamins, specifically B-12.
=== Proteasomal chaperones === In addition to DUBs and Ligases, many other proteins associate with the proteasome and are important for degradation. These proteins typically consist of a Ubiquitin-like domain (UBL) and a Ubiquitin associating domain (UBA) with Dsk2, Rad23, and Ddi1 being classified as Proteasomal Chaperones. Dsk2 and Rad23 have UBLs that bind the receptors of the proteasome. Ddi1 has been shown to bind long K48-Ubiquitin chains and act as a protease and is probably not directly interacting with the proteasome.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.